Novel Semi-Mechanistic Model Leveraging Preclinical and Clinical Data to Inform the Recommended Phase 2 Dose (RP2D) Selection for Epcoritamab (DuoBody CD3xCD20)
The DOI matches its Crossref record.
Abstract
Introduction: Epcoritamab (DuoBody-CD3×CD20) is a subcutaneously administered bispecific antibody (bsAb) that simultaneously binds to CD3 on T cells and CD20 on malignant B cells, resulting in T-cell activation and expansion and selective T-cell-mediated killing of CD20+ cells. Target engagement (TE) and crosslinking of CD3 and CD20 (trimer formation) lead to activation and expansion of T cells, which in turn leads to tumor cell killing and is the first step driving the pharmacology of epcoritamab. Hence, the optimal clinical dose of epcoritamab can be informed by TE and trimer formation. Unlike typical monoclonal antibodies, bsAbs exhibit a hook effect in which trimer formation is impaired at high drug concentrations. Therefore, targeting complete receptor occupancy can lead to suboptimal trimer formation and clinical efficacy; instead, the aim should be to identify epcoritamab concentrations that result in maximal trimer formation. Epcoritamab is currently being investigated in an ongoing, open-label, multi-center, first-in-human trial in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (NCT03625037). Endpoints include safety and identification of RP2D and pharmacokinetic/pharmacodynamic (PK/PD) analyses. Here, we present our approach for recommending the RP2D for epcoritamab based on a novel PK/PD model that predicts trimer formation. Methods: A semi-mechanistic PK/PD model was developed to quantitatively describe biodistribution of epcoritamab, trimer formation, and tumor response (Figure 1). This model makes use of preclinical data from cynomolgus monkeys, clinical PK/PD data, patient biomarker data, patient tumor characteristics, and response data. The model incorporates a minimal physiological-based PK model to predict epcoritamab concentration in tumors. The model also considers T- and B-cell dynamics, expression of CD3 and CD20 on these cells, and dynamic binding of epcoritamab to CD3 and CD20, as well as levels of trimer formation. Clinical trial simulations were performed using the PK/PD model, incorporating individual variability in key parameters, to predict the extent of trimer formation and tumor response in patients with diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). Variability in model parameters was based on either interindividual variability observed in the first-in-human trial or literature values. Results: The population PK/PD model was able to describe epcoritamab concentration-time profiles across doses (range: 0.0128-60 mg). Epcoritamab exhibited slow absorption, with Tmax of 2.8 days, a terminal half-life of 8.67 days, and target-mediated disposition (TMD). The model predicted the saturation of TMD to occur at dose levels ≥48 mg, indicating engagement and saturation of CD3 and CD20 in blood. In addition, the model was able to describe the exposure-response relationship observed in the clinic. Clinical trial simulations using the PK/PD model demonstrated that a 48-mg dose can achieve optimal trimer formation and clinical response in both FL and DLBCL. An exposure-adverse event analysis showed a flat relationship between epcoritamab exposure and risk of cytokine release syndrome (CRS) in the dose range evaluated. Based on these findings, 48 mg was identified as the potential RP2D for epcoritamab. Conclusions: For bsAbs such as epcoritamab, the optimal dose is one that leads to maximum trimer formation; hence, traditional PK modeling methodologies and exposure-response analyses are not adequate to guide RP2D selection. To overcome these limitations, we have developed a novel, semi-mechanistic PK/PD model incorporating preclinical, clinical, and patient biomarker data that identified the optimal dose for epcoritamab. This PK/PD model represents a novel approach and provides a general framework that can be applied to other CD3 bsAbs. Disclosures: Li: Genmab: Current Employment. Hiemstra:Genmab: Current Employment, Current equity holder in publicly-traded company. Chiu:Genmab: Current Employment. Oliveri:Genmab: Current Employment, Current equity holder in publicly-traded company. DeMarco:Genmab: Current Employment, Current equity holder in publicly-traded company. Salcedo:Genmab: Current Employment. Lihme Egerod:Genmab: Current Employment. Gupta:Genmab: Current Employment. OffLabel Disclosure: Epcoritamab is an investigational agent undergoing evaluation in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, unlike typical monoclonal antibodies (mAbs), bsAbs exhibit a “hook effect,” meaning that trimer formation is impaired at high drug concentrations. 5”
From Semimechanistic Physiologically‐Based Pharmacokinetic/Pharmacodynamic Model Informing Epcoritamab Dose Selection for Patients With B‐Cell Lymphomas (2022) · cites this paper as [5]
In the citing paper
“Therefore, the optimal clinical dose of epcoritamab can be informed by levels of target engagement and trimer formation. 4 , 5”
From Semimechanistic Physiologically‐Based Pharmacokinetic/Pharmacodynamic Model Informing Epcoritamab Dose Selection for Patients With B‐Cell Lymphomas (2022) · cites this paper as [5]
In the citing paper
“Thus, high receptor occupancy can lead to suboptimal trimer formation and suboptimal clinical efficacy, and traditional pharmacokinetic (PK)/pharmacodynamic (PD) modeling approaches may be inappropriate to identify the optimal dose of epcoritamab.”
From Semimechanistic Physiologically‐Based Pharmacokinetic/Pharmacodynamic Model Informing Epcoritamab Dose Selection for Patients With B‐Cell Lymphomas (2022) · cites this paper as [5]
In the citing paper
“Thus, high receptor occupancy can lead to suboptimal trimer formation and suboptimal clinical efficacy, and traditional pharmacokinetic (PK)/pharmacodynamic (PD) modeling approaches may be inappropriate to identify the optimal dose of epcoritamab.”
From Semimechanistic Physiologically‐Based Pharmacokinetic/Pharmacodynamic Model Informing Epcoritamab Dose Selection for Patients With B‐Cell Lymphomas (2022) · cites this paper as [5]
In the citing paper
“As discussed, dose optimization of bsAbs differs from that of mAbs due to the hook effect, 5 which can cause high levels of target engagement to reduce levels of trimer formation.”
From Semimechanistic Physiologically‐Based Pharmacokinetic/Pharmacodynamic Model Informing Epcoritamab Dose Selection for Patients With B‐Cell Lymphomas (2022) · cites this paper as [5]
Citations
Cites
Still being checked.
Cited by
Bispecific antibodies for the treatment of B-cell lymphoma: promises, unknowns, and opportunities
Falchi, L., Vardhana, S. A., & Salles, G. A. (2023) · Blood · doi:10.1182/blood.2021011994 · Cited by 208
Yin, N., Li, X., Zhang, X., Xue, S., Cao, Y., Niedermann, G., Lu, Y., & Xue, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01826-z · Cited by 79
Li, T., Hiemstra, I. H., Chiu, C., Oliveri, R. S., Elliott, B., DeMarco, D., Salcedo, T., Egerod, F. L., Sasser, K., Ahmadi, T., et al. (2022) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2729 · Cited by 34
Self-citationBispecific antibodies in indolent B-cell lymphomas
Radhakrishnan, V. S., & Davies, A. J. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1295599 · Cited by 15
Metadata
- Authors
- Li, T., Hiemstra, I. H., Chiu, C., Oliveri, R. S., DeMarco, D., Salcedo, T. W., Lihme Egerod, F., & Gupta, M.
- Affiliations
- Genmab (United States) (US)
- Genmab (Netherlands) (NL)
- Genmab (Denmark) (DK)
- Genmab, Copenhagen, Denmark
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2020-11-05
- Volume
- 136
- Issue
- Supplement 1
- Pages
- 35-36
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W3094948272
- Semantic Scholar
- 1250cb2eae5724f709c160f396adc51494086a58
- Cited by
- 4
- References
- 0
- Citations by year
- 2024: 2 · 2022: 2
- FWCI
- 0.24
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Blood (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Keywords
- epcoritamab, bispecific antibodies, recommended phase 2 dose, trimer formation, target engagement, hook effect, pharmacodynamic modeling, diffuse large B-cell lymphoma, relapsed/refractory lymphoma, tumor response prediction, T cell dynamics, B cell dynamics, interindividual variability
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Novel Semi-Mechanistic Model Leveraging Preclinical and Clinical Data to Inform the Recommended Phase 2 Dose (RP2D) Selection for Epcoritamab (DuoBody CD3xCD20). https://app.cochat.ai/papers/10.1182/blood-2020-139457
- The paper
- Li, T., Hiemstra, I. H., Chiu, C., Oliveri, R. S., DeMarco, D., Salcedo, T. W., Lihme Egerod, F., & Gupta, M. (2020). Novel Semi-Mechanistic Model Leveraging Preclinical and Clinical Data to Inform the Recommended Phase 2 Dose (RP2D) Selection for Epcoritamab (DuoBody CD3xCD20). Blood. https://doi.org/10.1182/blood-2020-139457
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.